Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Vertex Pharmaceuticals Incorporated < Previous 1 2 3 Next > Vertex to Participate in Upcoming June Investor Conferences May 22, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Jennifer Schneider Elected to Vertex Board of Directors May 15, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports First Quarter 2024 Financial Results May 06, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain April 18, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce First Quarter 2024 Financial Results on May 6 April 09, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease April 01, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) March 21, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Participate in Upcoming Investor Conferences February 20, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia February 13, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports Fourth Quarter and Full Year 2023 Financial Results February 05, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis February 05, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain January 30, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5 January 17, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia January 16, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia January 09, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings January 07, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8 December 18, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia December 15, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy December 13, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition December 11, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease December 08, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers CRSP VRTX Vertex Appoints Nancy Thornberry to its Board of Directors December 05, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5 November 23, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia November 16, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers CRSP VRTX Vertex Reports Third Quarter 2023 Financial Results November 06, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition November 02, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference November 02, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present at Upcoming Investor Conferences October 26, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce Third Quarter 2023 Financial Results on November 6 October 10, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Appoints Michel Lagarde to its Board of Directors October 05, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.